通过准FOXM1来开发具有强大的抗癌作用的干扰M1-20的开发
Huitong Bu1, Xianling Lan1, Haojie Cheng1
1State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, Hunan Engineering Research Center for Anticancer Targeted Protein Pharmaceuticals, Hunan University, Changsha, Hunan, 410082, China.
一种新型的,M1-20,有效地向FOXM1蛋白,抑制癌细胞生长和转移. 这种可以作为一种潜在的抗癌疗法,具有最小的副作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 蛋白与蛋白相互作用 (PPI) 在癌症中至关重要,是治疗点.
- 转录因子FOXM1在许多癌症中过度表达,使其成为一种关键的药物开发目标.
研究的目的:
- 设计和开发一种基于的新型治疗向FOXM1.1.
- 评估FOXM1-向M1-20的疗效和作用机制.
主要方法:
- 合理设计和选针对FOXM1.1.的化物库.
- 为提高稳定性,将类转化为D-逆向形式 (M1-20) 的优化.
- 评估M1-20对癌细胞增殖,迁移,亡和体内瘤进展的影响.
主要成果:
- 鉴定并优化了M1-20,一种稳定的,可以抑制FOXM1.1.
- M1-20抑制了癌细胞的增殖和迁移,同时诱导了亡.
- M1-20破坏了FOXM1与MuvB和CBP的相互作用,抑制了转录活性.
- 在体内研究表明,M1-20抑制了癌症的进展和转移,没有显著的毒性.
结论:
- M1-20是一种强大的FOXM1向性,具有已证明的抗癌活性.
- M1-20表现出有利的稳定性和安全性,表明其作为抗癌药物候选药物的潜力.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
相关概念视频
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
